Statistiche di base
| LEI | 52990034U7FZBKRAOE32 |
| CIK | 1553846 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Redhill Biopharma
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| June 2, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2026 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive office |
|
| May 27, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2026 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive offices |
|
| May 7, 2026 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-281417 PROSPECTUS SUPPLEMENT No. 3 (To Prospectus dated August 19, 2024) Up to $1,587,708 American Depositary Shares each representing ten thousand (10,000) Ordinary Shares RedHill Biopharma Ltd. This prospectus supplement dated May 5, 2026 (this “Prospectus Supplement”), supplements the information in the prospectus, dated August 19, 2024, for |
|
| May 4, 2026 |
As filed with the Securities and Exchange Commission on May 4, 2026 As filed with the Securities and Exchange Commission on May 4, 2026 Registration No. |
|
| April 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2026 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive offic |
|
| April 27, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURIT |
|
| April 27, 2026 |
CERTIFICATION BY CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 12.2 CERTIFICATION BY CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Razi Ingber certify that: 1. I have reviewed this annual report on Form 20-F of RedHill Biopharma Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of th |
|
| April 27, 2026 |
CONSENT OF INDEPENDENT AUDITORS Exhibit 15.3 CONSENT OF INDEPENDENT AUDITORS We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (file No. 333-281417, file No. 333-274957, file No. 333-273709, and file No. 333-254848) and the Registration Statements on Form S-8 (file No. 333-292879, file No. 333-286082, file No. 333-280327, file No. 333-273001, file No. 333-265845, file No. 333-262099, |
|
| April 27, 2026 |
CERTIFICATION BY CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 12.1 CERTIFICATION BY CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Dror Ben-Asher, certify that: 1. I have reviewed this annual report on Form 20-F of RedHill Biopharma Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light o |
|
| April 27, 2026 |
Exhibit 1.1 These Articles of Association are an unofficial translation of the Articles of Association in Hebrew adopted by the Company. The Articles of Association will take effect upon the public issuance of the Company Articles of Association of Redhill Biopharma Ltd. (“Company”) As last amended by the annual general meeting of shareholders on March 5, 2026 1 Table of Contents 1. Introduction 3 |
|
| April 27, 2026 |
Table of Contents Exhibit 15.1 The accompanying financial statements of Talicia Holdings Inc. (“THI”) are filed as an exhibit to the Annual Report on Form 20-F of RedHill Biopharma Ltd. for the fiscal year ended December 31, 2025, pursuant to Rule 3-09 of Regulation S-X of the U.S. Securities and Exchange Commission. The financial statements have been prepared in accordance with accounting princip |
|
| April 27, 2026 |
Exhibit 2.3 DESCRIPTION OF SHARE CAPITAL The following descriptions of our share capital and provisions of our amended and restated articles of association are summaries and do not purport to be complete. Our amended and restated articles of incorporation are filed with the SEC as an exhibit to our registration statement, of which this prospectus forms a part. Each of the American Depositary Share |
|
| April 27, 2026 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.2 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (file No. 333-281417, file No. 333-274957, file No. 333-273709, and file No. 333-254848) and the Registration Statements on Form S-8 (file No. 333-292879, file No.333-286082, file No.333-280327, file No. 333-273001, file No. 333-265845 |
|
| April 27, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2026 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive offic |
|
| April 27, 2026 |
Exhibit 13 CERTIFICATION BY CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of RedHill Biopharma Ltd. |
|
| April 22, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2026 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive offic |
|
| April 14, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2026 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive offic |
|
| March 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2026 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive offic |
|
| February 25, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2026 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive of |
|
| February 2, 2026 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-292528 PROSPECTUS REDHILL BIOPHARMA LTD. 6,465,559 AMERICAN DEPOSITARY SHARES REPRESENTING 64,655,590,000 ORDINARY SHARES This prospectus relates to the offer and sale, from time to time, of up to 6,465,559 American Depositary Shares (“ADSs”), by YA II PN, LTD. (“YA” or the “Selling Shareholder”), a Cayman Islands exempt limited partnership, in |
|
| January 27, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2026 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha’arba’a Street, Tel Aviv, 6473921, Israel (Address of principal executive off |
|
| January 22, 2026 |
Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 RedHill Biopharma Ltd. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Ordinary Shares, par value NIS 0.01 per share (1) Other 4,000,000,000 $ 0.0001 $ 400,000.00 0.0001381 $ 55.24 |
|
| January 22, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2026 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive off |
|
| January 22, 2026 |
As filed with the Securities and Exchange Commission on January 22, 2026 As filed with the Securities and Exchange Commission on January 22, 2026 Registration No. |
|
| January 22, 2026 |
Exhibit 4.1 These Articles of Association are an unofficial translation of the Articles of Association in Hebrew adopted by the Company. The Articles of Association will take effect upon the public issuance of the Company Articles of Association of Redhill Biopharma Ltd. (“Company”) As last amended by the annual general meeting of shareholders on May 26, 2025 Table of Contents 1. Introduction 3 2. |
|
| January 22, 2026 |
Registration No. As filed with the Securities and Exchange Commission on January 22, 2026 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 REDHILL BIOPHARMA LTD. (Exact name of registrant as specified in its charter) Israel (State or other jurisdiction of incorporation or organization) Not Applicable (I.R.S. Empl |
|
| January 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2026 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive off |
|
| December 31, 2025 |
EXCLUSIVE JOINT COMMERCIALIZATION AGREEMENT Exhibit 10.20 CONFIDENTIAL PURSUANT TO ITEM 601(b)(10) OF REGULATION S-K, CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED BY MEANS OF MARKING SUCH PORTIONS WITH ASTERISKS [*****] AS THE IDENTIFIED CONFIDENTIAL PORTIONS ARE BOTH NOT MATERIAL AND ARE THE TYPE OF INFORMATION THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. THE REGISTRANT AGREES TO SUPPLEMENTALLY FURNISH AN UNREDACTED |
|
| December 31, 2025 |
As filed with the Securities and Exchange Commission on December 31, 2025 As filed with the Securities and Exchange Commission on December 31, 2025 Registration No. |
|
| December 31, 2025 |
Exhibit 10.19 STOCK PURCHASE AGREEMENT THIS STOCK PURCHASE AGREEMENT is made as of October 17, 2025, between Talicia Holdings Inc., a Delaware company (“THI”), and Cumberland Pharmaceuticals Inc., a Tennessee company (“Cumberland”, and together with THI, the “Parties”). WHEREAS, RedHill BioPharma Ltd. (“RedHill”) has formed and incorporated THI to be engaged in the commercialization in the U.S. of |
|
| December 31, 2025 |
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION Overview On October 17, 2025 (the “Closing Date”), RedHill Biopharma Ltd. (“RedHill” or the “Company”) completed a strategic transaction regarding its proprietary drug, Talicia®. The transaction was effected through the sale to Cumberland Pharmaceuticals Inc. (“Cumberland”) of a portion of its holdings in Talicia Holding |
|
| December 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2025 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha’arba’a Street, Tel Aviv, 6473921, Israel (Address of principal executive of |
|
| December 31, 2025 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES F-1 RedHill Biopharma Ltd. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Ordinary Share |
|
| December 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2025 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha’arba’a Street, Tel Aviv, 6473921, Israel (Address of principal executive of |
|
| December 23, 2025 |
STANDBY EQUITY PURCHASE AGREEMENT Exhibit 99.1 STANDBY EQUITY PURCHASE AGREEMENT THIS STANDBY EQUITY PURCHASE AGREEMENT (this “Agreement”) dated as of December 19, 2025 is made by and between YA II PN, LTD., a Cayman Islands exempt limited company (the “Investor”), and REDHILL BIOPHARMA LTD., a company incorporated under the laws of the State of Israel (the “Company”). The Investor and the Company may be referred to herein individ |
|
| December 23, 2025 |
PREFUNDED ADS PURCHASE WARRANT REDHILL BIOPHARMA LTD. Exhibit 99.2 NEITHER THIS SECURITY NOR THE ORDINARY SHARES OR AMERICAN DEPOSITARY SHARES UNDERLYING THE SECURITIES REPRESENTED HEREBY HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY OTHER JURISDICTIONS. AS A RESULT THESE SECURITIES (INCLUDING THE ORDINARY SHARES AND THE AMERICAN DEPOSITARY SHARES UNDERLYING THESE SECURITIES) MAY NO |
|
| December 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2025 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive of |
|
| December 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2025 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive of |
|
| November 26, 2025 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-281417 PROSPECTUS SUPPLEMENT (To Prospectus Supplement dated February 3, 2025, to Prospectus dated August 19, 2024) Up to $352,267 American Depositary Shares each representing ten thousand (10,000) Ordinary Shares RedHill Biopharma Ltd. This prospectus supplement dated November 26, 2025 (this “Prospectus Supplement”), supplements the informatio |
|
| November 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2025 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha’arba’a Street, Tel Aviv, 6473921, Israel (Address of principal executive of |
|
| November 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2025 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive of |
|
| October 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2025 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive off |
|
| October 21, 2025 |
Exhibit 1.1 SIDE LETTER AGREEMENT This Side Letter Agreement (this “Side Letter Agreement”), dated as of October 20, 2025, is by and between Redhill Biopharma Ltd. (the “Company”) and Alumni Capital LP (“Alumni”). The Company and Alumni are collectively referred to herein as the “Parties”. WHEREAS, on June 20, 2025, the Company entered into that certain Any Market Purchase Agreement (the “Agreemen |
|
| October 21, 2025 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-288324 PROSPECTUS SUPPLEMENT NO. 1 (To Prospectus Dated September 9, 2025) REDHILL BIOPHARMA LTD. 4,582,582 AMERICAN DEPOSITARY SHARES REPRESENTING 45,825,820,000 ORDINARY SHARES This prospectus supplement (“Supplement”) modifies, supersedes and supplements certain information contained in, and should be read in conjunction with, that certain p |
|
| October 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2025 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive off |
|
| October 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2025 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive off |
|
| October 20, 2025 |
Exhibit 99.1 Press Release RedHill’s Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) invests $4 million in exchange for a 30% ownership stake and joint control in RedHill’s Talicia business - U.S. co-commercialization partnership designed to accelerate Talicia sales growth, leveraging Cumberland’s expand |
|
| October 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2025 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive off |
|
| September 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2025 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive o |
|
| September 9, 2025 |
X0101 EFFECT 33 LIVE 2025-09-09 0001178913-25-003255 POS AM 0001553846 RedHill Biopharma Ltd. 333-288324 |
|
| September 9, 2025 |
X0101 EFFECT 33 LIVE 2025-09-09 0001178913-25-003257 POS AM 0001553846 RedHill Biopharma Ltd. 333-276979 |
|
| September 5, 2025 |
As filed with the Securities and Exchange Commission on September 5, 2025 As filed with the Securities and Exchange Commission on September 5, 2025 Registration No. |
|
| September 5, 2025 |
Exhibit 99.3 You should read the following discussion of our financial condition and results of operations in conjunction with the financial statements and the notes thereto included elsewhere in the Form 6-K to which this discussion is an exhibit. Unless the context otherwise requires, all references to “RedHill,” “we,” “us,” “our,” the “Company” and similar designations refer to RedHill Biopharm |
|
| September 5, 2025 |
REDHILL BIOPHARMA LTD. CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION June 30, 2025 Table of Contents Exhibit 99.2 REDHILL BIOPHARMA LTD. CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION (UNAUDITED) June 30, 2025 1 Table of Contents REDHILL BIOPHARMA LTD. CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION (UNAUDITED) June 30, 2025 TABLE OF CONTENTS UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AS OF JUNE 30, 2025, IN U.S. DOLLARS: Page Condensed consolidated |
|
| September 5, 2025 |
REDHILL BIOPHARMA LTD. CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION June 30, 2025 Table of Contents Exhibit 99.2 REDHILL BIOPHARMA LTD. CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION (UNAUDITED) June 30, 2025 1 Table of Contents REDHILL BIOPHARMA LTD. CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION (UNAUDITED) June 30, 2025 TABLE OF CONTENTS UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AS OF JUNE 30, 2025, IN U.S. DOLLARS: Page Condensed consolidated |
|
| September 5, 2025 |
Exhibit 99.1 Press Release RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights Extensive strategic, financial and operational overhaul has reshaped and refocused our business; Strong progress on multiple fronts Commercial and R&D Highlights: · Recruitment initiated in the Bayer-supported Phase 2 combination study of opaganib and darolutamide in advanced prostat |
|
| September 5, 2025 |
Press Release RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights Extensive strategic, financial and operational overhaul has reshaped and refocused our business; Strong progress on multiple fronts Commercial and R&D Highlights: · Recruitment initiated in the Bayer-supported Phase 2 combination study of opaganib and darolutamide in advanced prostate cancer · Positive U. |
|
| September 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2025 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha’arba’a Street, Tel Aviv, 6473921, Israel (Address of principal executive o |
|
| September 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2025 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha’arba’a Street, Tel Aviv, 6473921, Israel (Address of principal executive |
|
| September 5, 2025 |
As filed with the Securities and Exchange Commission on September 5, 2025 As filed with the Securities and Exchange Commission on September 5, 2025 Registration No. |
|
| August 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2025 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive offi |
|
| August 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2025 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive offi |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2025 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha’arba’a Street, Tel Aviv, 6473921, Israel (Address of principal executive offi |
|
| July 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2025 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive office |
|
| July 2, 2025 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-288324 PROSPECTUS REDHILL BIOPHARMA LTD. 5,596,490 AMERICAN DEPOSITARY SHARES REPRESENTING 55,964,900,000 ORDINARY SHARES This prospectus relates to resale from time to time by the selling shareholder identified in this prospectus (the “Selling Shareholder”), of up to 5,596,490 American Depositary Shares (“ADSs”), each ADS representing ten thou |
|
| July 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2025 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive office |
|
| June 30, 2025 |
RedHill Biopharma Ltd. 21 Ha'arba'a Street Tel Aviv, 6473921, Israel RedHill Biopharma Ltd. 21 Ha'arba'a Street Tel Aviv, 6473921, Israel June 30, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street N.E. Washington, D.C. 20549 Attention: Lauren Hamill Re: RedHill Biopharma Ltd. Registration Statement on Form F-1 Filed June 25, 2025 File No. 333-288324 (the “Registration Statement”) Lad |
|
| June 30, 2025 |
June 30, 2025 Dror Ben-Asher Chief Executive Officer RedHill Biopharma Ltd. 21 Ha'arba'a Street Tel Aviv, 6473921, Israel Re: RedHill Biopharma Ltd. Registration Statement on Form F-1 Filed June 25, 2025 File No. 333-288324 Dear Dror Ben-Asher: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for a |
|
| June 25, 2025 |
Exhibit 10.7 RedHill Biopharma Ltd. (The "Company") Compensation Policy (the “Policy” or “Compensation Policy”) As last amended by the Company's Shareholders on May 26, 2025. 1. Definitions "Board of Directors" or “Board” - The Company's board of directors; "Committee" or "Compensation Committee" - The Company's compensation committee; "Company" - RedHill Biopharma Ltd.; "Companies Law" - The Comp |
|
| June 25, 2025 |
Exhibit 107 CALCULATION OF FILING FEE TABLE FORM F-1 (Form Type) REDHILL BIOPHARMA LTD. |
|
| June 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2025 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive office |
|
| June 25, 2025 |
Exhibit 3.1 These Articles of Association are an unofficial translation of the Articles of Association in Hebrew adopted by the Company. The Articles of Association will take effect upon the public issuance of the Company Articles of Association of Redhill Biopharma Ltd. (“Company”) As last amended by the annual general meeting of shareholders on May 26, 2025 Table of Contents 1. Introduction 3 2. |
|
| June 25, 2025 |
WARRANT REDHILL BIOPHARMA LTD. Exhibit 4.1 NEITHER THIS SECURITY NOR THE ORDINARY SHARES OR AMERICAN DEPOSITARY SHARES UNDERLYING THE SECURITIES REPRESENTED HEREBY HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY OTHER JURISDICTIONS. AS A RESULT, THESE SECURITIES (INCLUDING THE ORDINARY SHARES AND THE AMERICAN DEPOSITARY SHARES UNDERLYING THESE SECURITIES) MAY NO |
|
| June 25, 2025 |
Exhibit 1.1 Execution Version ANY MARKET PURCHASE AGREEMENT This Any Market Purchase Agreement (this “Agreement”), dated as of June 20, 2025 (the “Execution Date”), by and between Redhill Biopharma Ltd., an Israeli corporation (the “Company”), and Alumni Capital LP, a Delaware limited partnership (the “Investor”). RECITALS WHEREAS, subject to the terms and conditions set forth in this Agreement, t |
|
| June 25, 2025 |
As filed with the Securities and Exchange Commission on June 25, 2025 As filed with the Securities and Exchange Commission on June 25, 2025 Registration No. |
|
| June 25, 2025 |
PREFUNDED ADS PURCHASE WARRANT REDHILL BIOPHARMA LTD. Exhibit 4.2 NEITHER THIS SECURITY NOR THE ORDINARY SHARES OR AMERICAN DEPOSITARY SHARES UNDERLYING THE SECURITIES REPRESENTED HEREBY HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY OTHER JURISDICTIONS. AS A RESULT THESE SECURITIES (INCLUDING THE ORDINARY SHARES AND THE AMERICAN DEPOSITARY SHARES UNDERLYING THESE SECURITIES) MAY NOT |
|
| May 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2025 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive offices |
|
| May 19, 2025 |
Exhibit 1.1 May 14, 2025 [] Re: Reprice of Ordinary Share Purchase Warrants Dear Sirs/Madams: Redhill Biopharma Ltd. (the “Company”) is pleased to offer to you (the “Holder”) the opportunity to receive a reduction in the Exercise Price of the warrants to purchase ordinary shares represented by ADS issued to you on April 3, 2024 with respect to [] ADSs, each representing 10,000 Ordinary Shares of t |
|
| May 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2025 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive offices |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2025 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive offices |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2025 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive offices |
|
| May 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2025 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive offices |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive offic |
|
| April 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive offic |
|
| April 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive offic |
|
| April 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURIT |
|
| April 10, 2025 |
Exhibit 4.10 GLOBAL TERMINATION AGREEMENT This Global Termination Agreement (this “Termination Agreement”) is made as of July 19, 2024, by and between RedHill Biopharma Inc., a Delaware corporation (“RedHill”), RedHill Biopharma Ltd., an Israeli company (“RedHill Parent”), Movantik Acquisition Co., a Delaware corporation (“Movantik Acquisition”), Valinor Pharma, LLC, a Delaware limited liability c |
|
| April 10, 2025 |
Exhibit 2.3 DESCRIPTION OF SHARE CAPITAL The following descriptions of our share capital and provisions of our amended and restated articles of association are summaries and do not purport to be complete. Our amended and restated articles of incorporation are filed with the SEC as an exhibit to our registration statement, of which this prospectus forms a part. Each of the American Depositary Share |
|
| April 10, 2025 |
Exhibit 13 CERTIFICATION BY CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUAN TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of RedHill Biopharma Ltd. |
|
| April 10, 2025 |
CERTIFICATION BY CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 12.2 CERTIFICATION BY CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Razi Ingber certify that: 1. I have reviewed this annual report on Form 20-F of RedHill Biopharma Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of th |
|
| April 10, 2025 |
Exhibit 11.1 REDHILL BIOPHARMA LTD. GUIDELINES FOR THE HANDLING OF CORPORATE INFORMATION TO AVOID INSIDE INFORMATION LIABILITY These guidelines relate to the handling of material non-public information and are designed to promote compliance with securities laws by the members of the board of directors, executive officers, employees, and consultants who are team members identified by the Chief Exec |
|
| April 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive offic |
|
| April 10, 2025 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (file No. 333-281417, file No. 333-274957, file No. 333-273709, and file No. 333-254848) and the Registration Statements on Form S-8 (file No. 333-286082, file No. 333-280327, file No. 333-273001, file No. 333-265845, file No. 333-2620 |
|
| April 10, 2025 |
CERTIFICATION BY CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 12.1 CERTIFICATION BY CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Dror Ben-Asher, certify that: 1. I have reviewed this annual report on Form 20-F of RedHill Biopharma Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light o |
|
| April 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha’arba’a Street, Tel Aviv, 6473921, Israel (Address of principal executive offic |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha’arba’a Street, Tel Aviv, 6473921, Israel (Address of principal executive offic |
|
| March 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2025 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha’arba’a Street, Tel Aviv, 6473921, Israel (Address of principal executive offic |
|
| March 25, 2025 |
Exhibit 107 EX-FILING FEES Calculation of Filing Fee Tables Form S-8 (Form Type) RedHill Biopharma Ltd. |
|
| March 25, 2025 |
Registration No. As filed with the Securities and Exchange Commission on March 25, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 REDHILL BIOPHARMA LTD. (Exact name of registrant as specified in its charter) Israel (State or other jurisdiction of incorporation or organization) Not Applicable (I.R.S. Employ |
|
| March 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2025 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive offic |
|
| March 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2025 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive offic |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2025 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive of |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2025 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive of |
|
| February 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2025 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive of |
|
| February 3, 2025 |
AT THE MARKET OFFERING AGREEMENT Exhibit 1.1 AT THE MARKET OFFERING AGREEMENT February 3, 2025 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: RedHill Biopharma Ltd., a company organized under the laws of the State of Israel (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definitions. The terms that follow, when use |
|
| February 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2025 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha’arba’a Street, Tel Aviv, 6473921, Israel (Address of principal executive of |
|
| February 3, 2025 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-281417 PROSPECTUS SUPPLEMENT (To Prospectus dated August 19, 2024) Up to $3,464,000 American Depositary Shares each representing ten thousand (10,000) Ordinary Shares RedHill Biopharma Ltd. We have entered into an at the market offering agreement, dated February 3, 2025 (the “Sales Agreement”), with H.C. Wainwright & Co., LLC (“Wainwright”) rel |
|
| January 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2025 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive off |
|
| December 10, 2024 |
6-K 1 zk2432448.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address o |
|
| December 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive of |
|
| November 14, 2024 |
SC 13G/A 1 tm2428264d8sc13ga.htm SC 13G/A CUSIP No: 757468301 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 1)* RedHill Biopharma Ltd. (Name of Issuer) Ordinary Shares, NIS 0.01 par value per share (Title |
|
| October 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2024 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive off |
|
| October 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2024 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive off |
|
| October 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2024 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive off |
|
| October 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2024 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive off |
|
| September 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2024 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive o |
|
| September 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2024 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha’arba’a Street, Tel Aviv, 6473921, Israel (Address of principal executive o |
|
| September 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2024 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba’a Street, Tel Aviv, 6473921, Israel (Address of principal executive o |
|
| September 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2024 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive o |
|
| September 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2024 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive o |
|
| September 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2024 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha’arba’a Street, Tel Aviv, 6473921, Israel (Address of principal executive o |
|
| September 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2024 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive o |
|
| August 29, 2024 |
RedHill Biopharma Announces First Half 2024 Business Highlights A transformed RedHill: Press Release RedHill Biopharma Announces First Half 2024 Business Highlights A transformed RedHill: · Numerous potential catalysts · Strengthened cash balance and control over our destiny following the Termination Agreement with Movantik Acquisition Co. |
|
| August 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2024 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha’arba’a Street, Tel Aviv, 6473921, Israel (Address of principal executive offi |
|
| August 29, 2024 |
REDHILL BIOPHARMA LTD. CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION June 30, 2024 Table of Contents Exhibit 99.2 REDHILL BIOPHARMA LTD. CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION (UNAUDITED) June 30, 2024 1 Table of Contents REDHILL BIOPHARMA LTD. CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION (UNAUDITED) June 30, 2024 TABLE OF CONTENTS UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AS OF JUNE 30, 2024, IN U.S. DOLLARS: Page Condensed consolidated |
|
| August 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2024 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive offi |
|
| August 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2024 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive offi |
|
| August 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2024 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive offi |
|
| August 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2024 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive offi |
|
| August 15, 2024 |
August 15, 2024 Dror Ben-Asher Chief Executive Officer RedHill Biopharma Ltd. 21 Ha'arba'a Street Tel Aviv 6473921 Israel Re: RedHill Biopharma Ltd. Registration Statement on Form F-3 Filed August 9, 2024 File No. 333-281417 Dear Dror Ben-Asher: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for |
|
| August 15, 2024 |
RedHill Biopharma Ltd. 21 Ha'arba'a Street Tel Aviv, 6473921, Israel RedHill Biopharma Ltd. 21 Ha'arba'a Street Tel Aviv, 6473921, Israel August 15, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street N.E. Washington, D.C. 20549 Attention: Chris Edwards Re: RedHill Biopharma Ltd. Registration Statement on Form F-3 Filed August 9, 2024 File No. 333-281417 (the “Registration Statement”) |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2024 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive offi |
|
| August 13, 2024 |
424B3 1 redhill424b3.htm 424B3 Rule 424(b)(3) File No. 333-268713 Note: This revised form of American Depositary Receipt is being filed to reflect that the ratio of Shares per American Depositary Share has changed from four hundred shares to ten thousand shares, effective August 20, 2024. EXHIBIT A AMERICAN DEPOSITARY SHARES (Each American Depositary Share represents 10,000 deposited Shares) THE B |
|
| August 9, 2024 |
As filed with the Securities and Exchange Commission on August 9, 2024 As filed with the Securities and Exchange Commission on August 9, 2024 Registration No. |
|
| August 9, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) RedHill Biopharma Ltd. |
|
| August 7, 2024 |
Rule 424(b)(3) File No. 333-268713 Note: This revised form of American Depositary Receipt is being filed to reflect that the ratio of Shares per American Depositary Share has changed from four hundred shares to ten thousand shares, effective August 22, 2024. EXHIBIT A AMERICAN DEPOSITARY SHARES (Each American Depositary Share represents 10,000 deposited Shares) THE BANK OF NEW YORK MELLON AMERICAN |
|
| August 7, 2024 |
begin 644 avsignature2.pdf M)5!$1BTQ+C<-"B6AL\77#0HQ(# @;V)J#0H\/"]086=E41O8U1I=&QE M('1R=64^/CX^#0IE;F1O8FH-"C(@,"!O8FH-"CP\+T-O=6YT(#$O2VED7!E+U!A9V5S/CX-"F5N9&]B:@T*,R P(&]B:@T*/#PO0W)E M871I;VY$871E*$0Z,C R-# X,#'1' M4W1A=&4\/"]'4S<@-R P(%(@+T=3." X(# @4B ^/B]&;VYT/#[email protected] P M(%(@+T8R(#$S(# @4B ^/B]0CDV:0*FS OU'"X.(T.HN8^"P& M9K,L6)=K-5I;PCV-MEN"N)<@2K"!WVS;81$QZG)66Q2F%R@5DH>[2!YG,>%- MR4-% |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2024 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive offi |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2024 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive offi |
|
| July 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2024 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive office |
|
| July 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2024 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive office |
|
| June 20, 2024 |
Registration No. As filed with the Securities and Exchange Commission on [June 20, 2024] UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 REDHILL BIOPHARMA LTD. (Exact name of registrant as specified in its charter) Israel (State or other jurisdiction of incorporation or organization) Not Applicable (I.R.S. Emplo |
|
| June 20, 2024 |
Exhibit 107 EX-FILING FEES Calculation of Filing Fee Tables Form S-8 (Form Type) RedHill Biopharma Ltd. |
|
| June 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2024 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha’arba’a Street, Tel Aviv, 6473921, Israel (Address of principal executive office |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2024 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive office |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2024 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive offices |
|
| April 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2024 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive offic |
|
| April 18, 2024 |
As filed with the Securities and Exchange Commission on April 18, 2024 Table of Contents As filed with the Securities and Exchange Commission on April 18, 2024 Registration No. |
|
| April 8, 2024 |
CERTIFICATION BY CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 12.1 CERTIFICATION BY CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Dror Ben-Asher, certify that: 1. I have reviewed this annual report on Form 20-F of RedHill Biopharma Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light o |
|
| April 8, 2024 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (file No. 333-274957, file No. 333-273709, file No. 333-258259 and file No. 333-254848) and the Registration Statements on Form S-8 (file No. 333-273001, file No. 333-265845, file No. 333-262099, file No. 333-255710, file No. 333-25469 |
|
| April 8, 2024 |
CERTIFICATION BY CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 12.2 CERTIFICATION BY CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Razi Ingber certify that: 1. I have reviewed this annual report on Form 20-F of RedHill Biopharma Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of th |
|
| April 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2024 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive offic |
|
| April 8, 2024 |
REDHILL BIOPHARMA LTD. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Exhibit 97.1 REDHILL BIOPHARMA LTD. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION RedHill Biopharma Ltd. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of December 1, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 14. 1. Persons Subject to Pol |
|
| April 8, 2024 |
Exhibit 1.1 These Articles of Association are an unofficial translation of the Articles of Association in Hebrew adopted by the Company. The Articles of Association will take effect upon the public issuance of the Company Articles of Association of Redhill Biopharma Ltd. (“Company”) As approved by the extraordinary general meeting of shareholders on March 21, 2024 1 Table of Contents 1. Introducti |
|
| April 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURIT |
|
| April 8, 2024 |
Exhibit 13 CERTIFICATION BY CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUAN TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of RedHill Biopharma Ltd. |
|
| April 8, 2024 |
Exhibit 2.3 DESCRIPTION OF SHARE CAPITAL The following descriptions of our share capital and provisions of our amended and restated articles of association are summaries and do not purport to be complete. Our amended and restated articles of incorporation are filed with the SEC as an exhibit to our registration statement, of which this prospectus forms a part. Each of the American Depositary Share |
|
| April 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2024 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive offic |
|
| April 3, 2024 |
Exhibit 1.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of March 29, 2024, between RedHill Biopharma Ltd., a company organized under the laws of the State of Israel (the “Company”), and each investor identified on the signature pages hereto (each, including its successors and assigns, an “Investor” and collectively, the “Investors”). Subject to the |
|
| April 3, 2024 |
WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES REDHILL BIOPHARMA LTD. Exhibit 1.2 WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES REDHILL BIOPHARMA LTD. Number of American Depositary Shares: Issue Date: , 2024 Initial Exercise Date: , 2024 THIS WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and sub |
|
| April 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2024 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha’arba’a Street, Tel Aviv, 6473921, Israel (Address of principal executive offic |
|
| April 2, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-258259 PROSPECTUS SUPPLEMENT (To prospectus dated August 9, 2021) 2,144,487 American Depositary Shares representing 857,794,800 Ordinary Shares Warrants to Purchase up to 2,144,487 American Depositary Shares representing 857,794,800 Ordinary Shares Up to 2,144,487 American Depositary Shares representing 857,794,800 Ordinary Shares issuable upon |
|
| April 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2024 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive offic |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2024 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba’a Street, Tel Aviv, 6473921, Israel (Address of principal executive offic |
|
| March 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2024 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba’a Street, Tel Aviv, 6473921, Israel (Address of principal executive offic |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2024 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive offic |
|
| March 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2024 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive offic |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2024 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive offic |
|
| February 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2024 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive of |
|
| February 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2024 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive of |
|
| February 16, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-276979 PROSPECTUS 10,600,000 American Depositary Shares representing 4,240,000,000 Ordinary Shares REDHILL BIOPHARMA LTD. This prospectus relates to the resale from time to time by the selling shareholders named in this prospectus of up to an aggregate of 10,600,000 American Depositary Shares (the “Offered ADSs”), with each American Depositary |
|
| February 15, 2024 |
RedHill Biopharma Ltd. 21 Ha'arba'a Street Tel Aviv, 6473921, Israel RedHill Biopharma Ltd. 21 Ha'arba'a Street Tel Aviv, 6473921, Israel February 15, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street N.E. Washington, D.C. 20549 Attention: Tim Buchmiller Re: RedHill Biopharma Ltd. Registration Statement on Form F-1 Filed February 9, 2024 File No. 333-276979 (the “Registration Stateme |
|
| February 14, 2024 |
United States securities and exchange commission logo February 14, 2024 Dror Ben-Asher Chief Executive Officer RedHill Biopharma Ltd. |
|
| February 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2024 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive of |
|
| February 9, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form F-1 (Form Type) REDHILL BIOPHARMA LTD. |
|
| February 9, 2024 |
Exhibit 10.26 CERTAIN IDENTIFIED CONFIDENTIAL INFORMATION MARKED [***] HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS (I) THE TYPE THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL AND (II) NOT MATERIAL. CLINICAL TRIAL AGREEMENT This Clinical Trial Agreement (“Agreement”) effective as of the date of last signature below (“Effective Date”) is entered into by and between RedHill Biopharma Ltd., an Isr |
|
| February 9, 2024 |
Exhibit 3.1 These Articles of Association are an unofficial translation of the Articles of Association in Hebrew adopted by the Company. The Articles of Association will take effect upon the public issuance of the Company Articles of Association of Redhill Biopharma Ltd. (“Company”) As approved by the extraordinary general meeting of shareholders on November 29, 2023 Table of Contents 1. Introduct |
|
| February 9, 2024 |
As filed with the Securities and Exchange Commission on February 9, 2024 As filed with the Securities and Exchange Commission on February 9, 2024 Registration No. |
|
| February 2, 2024 |
EX-99.1 2 ea192753ex99-1redhill.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agre |
|
| February 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* RedHill Biopharma Ltd. (Name of Issuer) Ordinary shares, par value NIS 0.01 per share (Title of Class of Securities) 757468202** (CUSIP Number) January 25, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 1, 2024 |
US7574682024 / REDHILL BIOPHARMA LTD SP ADR / CVI Investments, Inc. - SC 13G Passive Investment CUSIP No: 757468202 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. )* RedHill Biopharma Ltd. (Name of Issuer) Ordinary Shares, NIS 0.01 par value per share (Title of Class of Securities) 757468202 (CUSIP N |
|
| January 26, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-258259 PROSPECTUS SUPPLEMENT (To prospectus dated August 9, 2021) 10,000,000 American Depositary Shares representing 4,000,000,000 Ordinary Shares RedHill Biopharma Ltd. We are offering 10,000,000 American Depositary Shares (“ADSs”), each ADS representing 400 ordinary shares, par value NIS 0.01 per share (the “Ordinary Shares”), in this offerin |
|
| January 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2024 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive off |
|
| January 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2024 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive off |
|
| January 26, 2024 |
WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES REDHILL BIOPHARMA LTD. Exhibit 1.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 26, 2024 |
Exhibit 1.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 25, 2024, between RedHill Biopharma Ltd., a company organized under the laws of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and, collectively, the “Purchasers”). WHEREAS, subject to |
|
| January 26, 2024 |
Exhibit 1.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2024 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive off |
|
| January 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2024 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive off |
|
| January 8, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* RedHill Biopharma Ltd. (Name of Issuer) Ordinary Shares, par value 0.01 NIS per share (Title of Class of Securities) 757468202** (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pu |
|
| January 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| December 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2023 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive of |
|
| December 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2023 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive of |
|
| December 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2023 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive of |
|
| December 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2023 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive of |
|
| December 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2023 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive of |
|
| November 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2023 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive of |
|
| November 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2023 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive of |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2023 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive of |
|
| October 26, 2023 |
RedHill Biopharma Ltd. 21 Ha'arba'a Street Tel Aviv, 6473921, Israel RedHill Biopharma Ltd. 21 Ha'arba'a Street Tel Aviv, 6473921, Israel October 26, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street N.E. Washington, D.C. 20549 Attention: Tim Buchmiller Re: RedHill Biopharma Ltd. Registration Statement on Form F-3 Filed October 13, 2023 File No. 333-274957 (the “Registration Statemen |
|
| October 26, 2023 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-274957 PROSPECTUS 8,861,961 American Depositary Shares representing 3,544,784,400 Ordinary Shares REDHILL BIOPHARMA LTD. This prospectus relates to the resale by the selling shareholders named in this prospectus from time to time of up to an aggregate of 8,861,961 American Depositary Shares (the “Offered ADSs”), with each American Depositary Sh |
|
| October 23, 2023 |
As filed with the Securities and Exchange Commission on October 23, 2023 As filed with the Securities and Exchange Commission on October 23, 2023 Registration No. |
|
| October 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2023 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive off |
|
| October 13, 2023 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form F-3 (Form Type) REDHILL BIOPHARMA LTD. |
|
| October 13, 2023 |
As filed with the Securities and Exchange Commission on October 13, 2023 As filed with the Securities and Exchange Commission on October 13, 2023 Registration No. |
|
| October 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2023 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive off |
|
| October 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2023 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive off |
|
| September 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2023 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive o |
|
| September 29, 2023 |
Annex A – Representations and Warranties Exhibit 1.1 September 28, 2023 Holder of Ordinary Share Purchase Warrants Re: Reprice and Reload Offer of Ordinary Share Purchase Warrants To Whom It May Concern: RedHill Biopharma Ltd. (the “Company”) is pleased to offer to you (the “Holder”) the opportunity to receive (i) new warrants of the Company to purchase ordinary shares represented by American Depositary Shares (“ADSs”) and (ii) a reducti |
|
| September 29, 2023 |
WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES REDHILL BIOPHARMA LTD. Exhibit 1.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| September 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2023 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive o |
|
| September 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2023 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive o |
|
| September 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2023 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive o |
|
| August 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2023 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive offi |
|
| August 17, 2023 |
Press Release RedHill Biopharma Provides H1/23 Financial Results and Operational Highlights RHB-107 included in the U. |
|
| August 17, 2023 |
REDHILL BIOPHARMA LTD. CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION June 2023 Table of Contents Exhibit 99.2 REDHILL BIOPHARMA LTD. CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION (UNAUDITED) June 2023 Table of Contents REDHILL BIOPHARMA LTD. CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION (UNAUDITED) June 30, 2023 TABLE OF CONTENTS UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AS OF JUNE 30, 2023, IN U.S. DOLLARS: Page Condensed consolidated inter |
|
| August 11, 2023 |
1,998,221 American Depositary Shares representing 799,288,400 Ordinary Shares REDHILL BIOPHARMA LTD. Filed Pursuant to Rule 424(b)(3) Registration No. 333-273709 PROSPECTUS 1,998,221 American Depositary Shares representing 799,288,400 Ordinary Shares REDHILL BIOPHARMA LTD. This prospectus relates to the resale by the selling shareholders named in this prospectus from time to time of up to an aggregate of 1,998,221 American Depositary Shares (“Offered ADSs”), with each American Depositary Share (“ |
|
| August 9, 2023 |
United States securities and exchange commission logo August 9, 2023 Dror Ben-Asher Chief Executive Officer and Director RedHill Biopharma Ltd. |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2023 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive offi |
|
| August 9, 2023 |
RedHill Biopharma Ltd. 21 Ha'arba'a Street Tel Aviv, 6473921, Israel RedHill Biopharma Ltd. 21 Ha'arba'a Street Tel Aviv, 6473921, Israel August 9, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street N.E. Washington, D.C. 20549 Attention: Daniel Crawford Re: RedHill Biopharma Ltd. Registration Statement on Form F-3 Filed August 4, 2023 File No. 333-273709 Ladies and Gentlemen: Pursuant |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2023 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive offi |
|
| August 4, 2023 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form F-3 (Form Type) REDHILL BIOPHARMA LTD. |
|
| August 4, 2023 |
As filed with the Securities and Exchange Commission on August 4, 2023 As filed with the Securities and Exchange Commission on August 4, 2023 Registration No. |
|
| August 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2023 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive offi |
|
| July 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2023 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive office |
|
| July 25, 2023 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-258259 PROSPECTUS SUPPLEMENT (To Prospectus Supplement Dated December 2, 2022 to Prospectus Dated August 9, 2021) 544,375 Units Each Consisting of One American Depositary Share and One Warrant to Purchase One American Depositary Share 255,625 Pre-Funded Units Each Consisting of One Pre-Funded Warrant to Purchase One American Depositary Share an |
|
| July 25, 2023 |
Exhibit 1.2 PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES REDHILL BIOPHARMA LTD. Number of American Depositary Shares: Issue Date: July , 2023 THIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subjec |
|
| July 25, 2023 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-258259 PROSPECTUS SUPPLEMENT (To Prospectus Supplement Dated March 30, 2023 to Prospectus Dated August 9, 2021) 270,000 American Depositary Shares representing 108,000,000 Ordinary Shares Pre-funded Warrants to Purchase up to 1,230,000 American Depositary Shares Series A Warrants to purchase up to 1,500,000 American Depositary Shares Series B W |
|
| July 25, 2023 |
WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES REDHILL BIOPHARMA LTD. Exhibit 1.5 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| July 25, 2023 |
Exhibit 1.6 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| July 25, 2023 |
Exhibit 5.1 July 24, 2023 RedHill Biopharma Ltd. 21 Ha'arba'a Street Tel Aviv, 6473921 Israel Ladies and Gentlemen: We have acted as Israeli counsel to RedHill Biopharma Ltd. (the “Company”), an Israeli company, in connection with the issue and sale by the Company of it securities, consisting of (i) 1,084,923 American Depositary Shares (the "Offering ADSs"), each representing 400 ordinary shares ( |
|
| July 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2023 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive office |
|
| July 25, 2023 |
Annex A – Representations and Warranties Exhibit 1.4 July 21, 2023 Re: Reprice and Reload Offer of Ordinary Share Purchase Warrants To Whom It May Concern: Redhill Biopharma Ltd. (the “Company”) is pleased to offer to you (the “Holder”) the opportunity to receive (i) new warrants of the Company to purchase ordinary shares represented by American Depositary Shares (“ADSs”) and (ii) a reduction in the Exercise Price of the Class B warrants |
|
| July 25, 2023 |
Exhibit 5.2 July 25, 2023 RedHill Biopharma Ltd. 21 Ha'arba'a Street Tel Aviv, Israel 6473921 Ladies and Gentlemen: We have acted as special U.S. counsel to RedHill Biopharma Ltd., an Israeli company (the “Company”), in connection with the offering by the Company of (i) 1,084,923 American Depositary Shares (the “ADSs”), each ADS representing four hundred (400) ordinary shares of the Company, par v |
|
| July 25, 2023 |
Exhibit 1.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July , 2023, between RedHill Biopharma Ltd., a company organized under the laws of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and, collectively, the “Purchasers”). WHEREAS, subject to the t |
|
| July 25, 2023 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-258259 PROSPECTUS SUPPLEMENT (To prospectus dated August 9, 2021) 1,084,923 American Depositary Shares representing 433,969,200 Ordinary Shares Pre-funded Warrants to Purchase up to 217,000 American Depositary Shares Up to 217,000 American Depositary Shares representing 86,800,000 Ordinary Shares underlying the Pre-funded Warrants RedHill Bioph |
|
| July 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2023 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive office |
|
| July 25, 2023 |
Exhibit 1.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| July 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2023 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive office |
|
| July 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2023 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive office |
|
| July 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2023 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive office |
|
| June 29, 2023 |
Registration No. As filed with the Securities and Exchange Commission on June 29, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 REDHILL BIOPHARMA LTD. (Exact name of registrant as specified in its charter) Israel (State or other jurisdiction of incorporation or organization) Not Applicable (I.R.S. Employe |
|
| June 29, 2023 |
Exhibit 107 EX-FILING FEES Calculation of Filing Fee Tables Form S-8 (Form Type) RedHill Biopharma Ltd. |
|
| June 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2023 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive office |
|
| June 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2023 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive office |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2023 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive offices |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2023 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive offices |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2023 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive offices |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2023 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive offices |
|
| May 1, 2023 |
6-K 1 zk2329614.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2023 Commission File No.:001-35773 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of pri |
